Figure 2.

MEKi-associated skin toxicity can be reduced by addition of BRSFi.

Notes: The occurrence of skin toxicity was evaluated in a Kaplan–Meier analysis for the cohort of mice. The arrow indicates the moment at which treatments were switched for the mice. Representative macroscopic examples of skin toxicity observed after 58 days of GSK212 treatment (C). Representative hematoxylin and eosin (H&E) stain of skin from a single GSK212 treated mouse and inflamed skin from a combination PLX4720+GSK212 treated mouse after 26 and 172 days of treatment, respectively (D).

Abbreviations: MEK, mitogen-activated protein kinase kinase; MEKi, MEK inhibitor; BRAFi, BRAF inhibitor; GSK212, GSK1120212.